Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
30.04.2025 10:00:00
|
DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care
Recognized for Advancing Global Wound Care Through Innovation and Efficacy
AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, the flagship product of DEBx Medical has been awarded the IIWCG Achievement Award 2025 for Innovation in Wound Care at the 16th Abu Dhabi Wound Care Conference.
Presented during the Opening Ceremony at ADNEC, this recognition by the International Interprofessional Wound Care Group (IIWCG) honors excellence in wound care and spotlights breakthroughs redefining standards in chronic wound management through innovation and efficacy.
It is not only an honor for DEBx Medical—it’s a tribute to the clinical judgment of many clinicians who continue to put DEBRICHEM® into practice and improve outcomes, even in the most challenging cases.
DEBRICHEM®: One Application. First Line. Debridement Solution.
With just one 60-second application, DEBRICHEM® eradicates devitalized tissue, infection, and biofilm from chronic wounds, key barriers that prevent healing from progressing.
For clinicians, it offers:
- Rapid, targeted action, reopening the pathway to healing
- An easy-to-use approach for multifactorial wounds
- A results-driven practical solution in high-pressure settings
For healthcare systems and patients, it enables:
- Fewer interventions and lower resource use
- Better patient compliance across different wound etiologies
- Potential reduced reliance on antibiotics, helping to counter antimicrobial resistance
- A meaningful step forward in the fight against amputations
Backed by scientific evidence, DEBRICHEM® supports clinicians in both advanced hospital settings and remote or resource-limited environments.
In a time when healthcare efficiency and antimicrobial resistance are pressing global concerns, innovation like DEBRICHEM® is not just valuable, it’s vital.
"It’s a moment of shared pride and purpose. This recognition by the IIWCG is an incredible honor, not just for DEBx Medical, but for every clinician and patient who places their trust in innovation. DEBRICHEM® was developed to meet a critical gap in chronic wound care. This award validates the real-world impact our team strives for every day: restoring dignity, preserving limbs, improving lives.”— Bert Quint, CEO, DEBx Medical
The award underscores DEBx Medical’s commitment to advancing wound care that prioritizes patient progress above all.
About DEBx Medical
DEBx Medical is a medical technology business dedicated to revolutionizing the management of chronic wounds. It focuses on delivering disruptive and efficient wound care treatments that are easy to use and implement in daily clinical practice: DEBRICHEM® - Innovating The Future of Wound Care
For inquiries:
DEBx Medical: Chandrita Jaisinghani, press@debx-medical.com, +31 85 0878096

Analysen zu Mitsubishi Materials Corp
Die David-Schere erklärt: 5 Kennzahlen für starke Aktien – am Beispiel von SAP
Seit Anfang 2023 präsentieren der Investment-Stratege François Bloch und Börsenexperte David Kunz jeweils drei sorgfältig ausgewählte Aktien im BX Morningcall.
Eine Begrifflichkeit, die im Zusammenhang mit der Titelauswahl immer wieder fällt, ist die «David-Schere».
Was verbirgt sich hinter der #David-Schere? In diesem Video erklärt François Bloch, warum diese Methode zur #Aktienbewertung eine echte Geheimwaffe ist – und was sie so treffsicher macht.
Gemeinsam mit David Kunz nehmen wir den Technologiegiganten #SAP unter die Lupe und zeigen anhand von fünf Kennzahlen, warum diese Aktie derzeit besonders spannend ist.:
✅ Umsatz
✅ EBIT
✅ EBIT Marge
✅ Dividende
✅ Gewinn pro Aktie
Pünktlich zum Börsenstart diskutieren Investment-Stratege François Bloch und Börsen-Experte David Kunz oder Olivia Hähnel über ausgewählte Top-Aktienwerte aus dem BX Musterportfolio.
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Nach Fed-Zinsentscheid: SMI schliesst tiefer -- DAX letztlich stärker -- Asiens Börsen beenden den Handel freundlichDer heimische Aktienmarkt zeigte sich tiefer. Der deutsche Aktienmarkt legte am Donnerstag zu. Die US-Börsen notieren am Donnerstag deutlich im Plus. An den Aktienmärkten in Fernost ging es am Mittwoch aufwärts.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |